BST Update
BST Position Update: June 18, 2013
June 18, 2013 . . . . Rockwell Medical (NASDAQ: RMTI) – Buy up to $4.40 RMTI is our most recent biotech recommendation. They’re developing Soluble Ferric Phosphate (SFP) for iron therapy treatment in patients with chronic kidney disease. Rockwell believes SFP will provide significant improvement over current IV iron therapy for dialysis patients. Unlike […]
BST Position Update: May 16, 2013
May 16, 2013 . . . . AcelRx Pharmaceuticals (NASDAQ: ACRX) – Sell ACRX is on fire! The biotech’s shares soared to a new high of $7.30 just yesterday. Investors have clearly piled into the stock ahead of the upcoming phase 3 trial data for ARX-01. Those results are expected before the end of the […]
BST Position Update: April 4, 2013
April 4, 2013 . . . . AcelRx Pharmaceuticals (NASDAQ: ACRX) – Buy up to $5.65 ACRX is the latest addition to the portfolio. They’re developing the Sufentanil NanoTab® PCA system (also known as ARX-01) which allows patients to manage their post-operative pain following surgery. At the moment, surgical patients manage their post-operative pain with […]
BST Position Update: March 22, 2013
March 22, 2013 . . . . Anacor Pharmaceuticals (NASDAQ: ANAC) – Hold It’s a good thing we decided to hang on to ANAC. The stock surged 26% yesterdayon heavy volume. And we now have a 3% gain on the position. ANAC soared on positive data from a phase 2 trial of AN2728, the company’s novel treatment for […]
BST Position Update: March 11, 2013
March 11, 2013 . . . . Halozyme Therapeutics (NASDAQ: HALO) – Buy up to $6.00 HALO is our most recent addition to the portfolio. And to say we’re excited about another opportunity to trade this biotech, would be an understatement. The last time we traded it, our position more than doubled in value. And […]
BST Position Update: February 15, 2013
February 15, 2013 . . . . MannKind (NASDAQ: MNKD) – Buy up to $2.85 MNKD is our latest addition to the portfolio. And we’re very excited about it to say the least. They’re developing a potential blockbuster drug called Afrezza for type 1 and type 2 diabetes. Why are we so high on Afrezza? […]
BST Position Update: January 18, 2013
January 18, 2013 . . . . Array BioPharma (NASDAQ: ARRY) – Buy up to $4.80 We’re very excited about our latest addition to the portfolio, Array BioPharma. This small biotech is developing a number of drugs to treat cancer and inflammatory diseases. Why are we so excited? ARRY has a robust pipeline of 14 […]
BST Position Update: January 4, 2013
January 4, 2013 . . . . Trius Therapeutics (NASDAQ: TSRX) – Hold In our last update, we urged you to view the pullback in TSRX as a buying opportunity. We believed then, as we do now, that investors would push the stock higher ahead of the upcoming phase 3 trial results for tedizolid phosphate. […]
